Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease
Authors not listed
vTv Therapeutics · 2016
Abstract
This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2016). Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease. <em>vTv Therapeutics</em>. https://clinicaltrials.gov/study/NCT02916056
Vancouver
Anonymous. Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease. vTv Therapeutics. 2016.
BibTeX
@misc{anon2016OpenLa,
title = {Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease},
author = {Anonymous},
journal = {vTv Therapeutics},
year = {2016},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Pfizer 2008
Open access · US-GOV
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Anavex Life Sciences Corp. 2016
Open access · US-GOV
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
H. Lundbeck A/S 2015
Open access · US-GOV
Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease
Beijing Friendship Hospital 2016
Open access · US-GOV
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease: A Multi-center Single-arm Study in China
Medivation, Inc. 2008
Open access · US-GOV
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Adam Boxer 2017
Open access · US-GOV